Endometrial Biopsy in Progestin Contraceptive Users - Trial NCT05760144
Access comprehensive clinical trial information for NCT05760144 through Pure Global AI's free database. This Phase 1 trial is sponsored by Oregon Health and Science University and is currently Recruiting. The study focuses on Contraception. Target enrollment is 52 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Oregon Health and Science University
Timeline & Enrollment
Phase 1
Apr 01, 2023
Nov 01, 2025
Primary Outcome
The proportion of participants who experienced endometrial changes
Summary
The purpose of the study is to learn more about menstrual changes in progestin contraception
 users. The investigators are hoping to find out what changes in the endometrium lead to
 different bleeding patterns during the first year of progestin contraception use.
 Participants will choose to receive the contraceptive implant (Etonogestrel implant also
 called Nexplanon) or the contraceptive injectable (Depo-medroxyprogesterone acetate (DMPA)
 also called Depo-Provera) for up to 12 months. They will be asked to have 4 endometrial
 biopsies over the course of the study, as well as blood draws, physical exams, and pregnancy
 tests. Participants will also use a daily text message or email diary to report bleeding
 patterns. This study's plan is to comprehensively phenotype bleeding patterns and profile the
 entire endometrium using single-cell RNA seq data (sCRNAseq).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05760144
Non-Device Trial